Articles | Open Access | DOI: https://doi.org/10.55640/eijmrms-02-12-14

EVALUATING THE EFFICACY OF TARGET PXT IN METASTATIC LIVER TUMORS

Mamatkulov Panji Khasanovich , Surkhandarya Branch Of Rio And Riatm, Uzbekistan
Amanov Akmaljon Karimjonovich , Assistant, Termez Branch Of Tashkent Medical Academy, Uzbekistan
Soatov Umidjon Abduganievich , Assistant, Termez Branch Of Tashkent Medical Academy, Uzbekistan
Juraeva Gulbakhor Alisherovna , Assistant, Termez Branch Of Tashkent Medical Academy, Uzbekistan

Abstract

The goal of assessing tumour response on imaging is to identify patients who are likely to benefit — or not — from anticancer treatment, especially in relation to survival. The World Health Organization was the first to develop assessment criteria. This early score, which assessed tumour burden by standardising lesion size measurements, laid the groundwork for many of the criteria that followed. This was then improved by the Response Evaluation Criteria in Solid Tumours (RECIST) which was quickly adopted by the oncology community. At the same time, many interventional oncology treatments were developed to target specific features of liver tumours that result in significant changes in tumours but have little effect on tumour size. New criteria focusing on the viable part of tumours were therefore designed to provide more appropriate feedback to guide patient management. Targeted therapy has resulted in a breakthrough that challenges conventional response criteria due to the non-linear relationship between response and tumour size, requiring the development of methods that emphasize the appearance of tumours. More recently, research into functional and quantitative imaging has created new opportunities in liver imaging. These results have suggested that certain parameters could serve as early predictors of response or could predict later tumour response at baseline. These approaches have now been extended by machine learning and deep learning. This clinical review focuses on the progress made in the evaluation of liver tumours on imaging, discussing the rationale for this approach, addressing challenges and controversies in the field, and suggesting possible future developments.

Keywords

Liver, Imaging, Tumours

References

Organization W.H. World Health Organization; sold by WHO Publications Centre USA; Geneva and Albany, NY: 1979. WHO Handbook for Reporting Results of Cancer Treatment. [Google Scholar]

Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216. [PubMed] [Google Scholar]

Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. [PubMed] [Google Scholar]

Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. [PubMed] [Google Scholar]

Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430. [

Article Statistics

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Copyright License

Download Citations

How to Cite

Mamatkulov Panji Khasanovich, Amanov Akmaljon Karimjonovich, Soatov Umidjon Abduganievich, & Juraeva Gulbakhor Alisherovna. (2022). EVALUATING THE EFFICACY OF TARGET PXT IN METASTATIC LIVER TUMORS. European International Journal of Multidisciplinary Research and Management Studies, 2(12), 63–66. https://doi.org/10.55640/eijmrms-02-12-14